GeneTex Webinar

SARS-CoV-2 Omicron therapeutics

We would like to invite you to participate in our partner company GeneTex's upcoming webinar on SARS-CoV-2 Omicron therapeutics.

Webinar: SARS-CoV-2 Omicron therapeutics - Getting to know the unknown and the road ahead

As SARS-CoV-2 Omicron variants continue to dominate around the world and accumulate novel mutations leading to immune evasion, antiviral treatments are becoming increasingly important to limit hospitalizations and death due to COVID-19. Studies are still lacking to understand which combination therapy approaches will have the greatest potency and synergy against SARS-CoV-2 Omicron sub-variants. Dr. Jean will present the recent discovery of novel pan-coronavirus antiviral drugs directed at viral and host-cell enzymes. He will discuss their applications as direct-acting antivirals (DAAs) and host-directed antivirals (HDAs) against SARS-CoV-2 Omicron variants when used alone or in combination in 2D and 3D cell-based systems of viral infection. This work will provide new insights into the unique biology of SARS-CoV-2 Omicron variants, and unravel potential combination antiviral therapies based on HDAs and DAAs acting synergistically as alternatives to monotherapy to improve COVID-19 treatment.

Speaker: François Jean, Ph.D., is an expert in antiviral drug discovery and Professor of Molecular Virology at the University of British Columbia (UBC). He is the founder of UBC’s Facility for Infectious Disease and Epidemic Research (FINDER), one of the largest university-based containment level 3 (CL-3) facilities in the world.